HIPEC outcomes vary widely between centres. Knowing what determines success helps patients ask the right questions and choose the right team.
On this page
- 1. Completeness of cytoreduction (CC score)
- 2. Peritoneal Cancer Index (PCI) score
- 3. Surgeon and centre volume
- 4. Cancer type and histology
- 5. Patient fitness for major surgery
- 6. Chemotherapy agent and protocol
- 7. Multi-disciplinary team support
- 8. Timing in the treatment journey
- 9. Post-operative care quality
Factors that affect hipec success — 1. Completeness of cytoreduction (CC score)
The single most important factor. CC-0 (no visible residual disease) and CC-1 (residual under 2.5mm) are associated with the best survival. CC-2 and CC-3 results predict poor outcomes. Surgeon experience directly impacts the ability to achieve CC-0/1.
2. Peritoneal Cancer Index (PCI) score
PCI scores extent of peritoneal disease across 13 abdominal regions. PCI under 20 has significantly better outcomes than PCI over 20. Patient selection based on PCI matters.
3. Surgeon and centre volume
Centres performing 25+ HIPEC procedures annually have measurably better complication rates and survival than low-volume centres. Ask about volume.
4. Cancer type and histology
Pseudomyxoma peritonei and selected ovarian cancers have the most established benefit. Colorectal peritoneal disease has selective benefit. Aggressive histologies (mucinous, signet-ring) respond less well.
5. Patient fitness for major surgery
HIPEC + cytoreductive surgery is a major procedure. Age alone is not a barrier, but performance status, cardiac and pulmonary function, and nutritional state must support a 6-10 hour operation.
6. Chemotherapy agent and protocol
Different agents (cisplatin, mitomycin-C, oxaliplatin, doxorubicin) are used for different cancers. Temperature (41-43°C) and duration (60-90 min) must be standardised to recognised protocols.
7. Multi-disciplinary team support
A HIPEC programme needs trained anaesthesia, intensive care, perfusion technology, and oncology pharmacy. A solo surgeon without team support is a warning sign.
8. Timing in the treatment journey
HIPEC at the time of primary cytoreduction (after neoadjuvant chemotherapy) has clearer evidence than HIPEC for recurrent disease. Timing is critical.
9. Post-operative care quality
Enhanced recovery protocols, prompt mobilisation, careful fluid management, and prevention of post-operative complications all affect outcomes. The first 7 days after HIPEC are crucial.
What to do next
For an honest, evidence-based assessment of whether HIPEC is appropriate for you and which centre is right, request a second opinion with Dr. Nishtha Tripathi Patel. WhatsApp your reports to +91 76988 00333.
Related
External reference: Van Driel et al., NEJM HIPEC trial.
FAQs
Completeness of cytoreduction (CC score)
The single most important factor. CC-0 (no visible residual disease) and CC-1 (residual under 2.5mm) are associated with the best survival. CC-2 and CC-3 results predict poor outcomes. Surgeon experience directly impacts the ability to achieve CC-0/1.
Peritoneal Cancer Index (PCI) score
PCI scores extent of peritoneal disease across 13 abdominal regions. PCI under 20 has significantly better outcomes than PCI over 20. Patient selection based on PCI matters.
Surgeon and centre volume
Centres performing 25+ HIPEC procedures annually have measurably better complication rates and survival than low-volume centres. Ask about volume.
Cancer type and histology
Pseudomyxoma peritonei and selected ovarian cancers have the most established benefit. Colorectal peritoneal disease has selective benefit. Aggressive histologies (mucinous, signet-ring) respond less well.
Patient fitness for major surgery
HIPEC + cytoreductive surgery is a major procedure. Age alone is not a barrier, but performance status, cardiac and pulmonary function, and nutritional state must support a 6-10 hour operation.
Consultation and Next Steps
For an individualised consultation on factors that affect hipec success, share your reports on WhatsApp at +91 76988 00333. Dr. Nishtha Tripathi Patel provides a detailed assessment within 24-48 hours and arranges in-person consultation at Sterling Hospitals, KD Hospital, or Welcare Speciality Hospital in Ahmedabad based on your location and treatment requirements.
Bring the following to your first consultation: imaging studies (ultrasound, CT or MRI on CD), histopathology and biopsy reports, tumour marker results (CA-125, HE4, CEA where relevant), a list of current medications, and any prior treatment summaries. For patients travelling from outside Ahmedabad, scheduling can be arranged to complete consultation and any pre-op work-up in the fewest possible visits.
If you are exploring second-opinion options, see our second-opinion service page. Independent review of diagnosis, staging, and proposed treatment plans is provided at no cost via WhatsApp report review. You do not need to switch hospitals to obtain a second opinion.
For broader information about factors that affect hipec success and related conditions, also see our complete ovarian cancer guide, HIPEC India guide, cervical cancer guide and robotic surgery guide.
Reviewed by Dr. Nishtha Tripathi Patel, MBBS, DGO, DNB, Fellowship Gynaecological Oncology, ESGO-certified.